Blood cancer journal
Journal
Overview
publication venue for
-
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study..
14.
2024
-
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms..
14.
2024
-
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group..
12.
2022
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies..
12.
2022
-
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma..
12.
2022
-
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine..
11.
2021
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial..
11.
2021
-
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia..
11.
2021
-
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma..
10.
2020
-
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups..
10.
2020
-
Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice..
10.
2020
-
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis..
10.
2020
-
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse..
9.
2019
-
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma..
9.
2019
-
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials..
8.
2018
-
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay..
8.
2018
-
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment..
7.
2017
-
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells..
6.
2016
-
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma..
5.
2015
-
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies..
5.
2015
-
Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma..
4.
2014
-
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified..
4.
2014
-
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma..
4.
2014
-
Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups..
4.
2014
-
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma..
4.
2014
-
Cancer-testis antigen expression and immunogenicity in AL amyloidosis..
2.
2012
-
Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms..
1.
2011
-
Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia..
1.
2011
-
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features..
10.
2020
-
Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse..
9.
2019
-
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project..
8.
2018
-
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care..
7.
2017
-
MicroRNA-155 regulates casein kinase 1 gamma 2: a potential pathogenetic role in chronic lymphocytic leukemia..
7.
2017
-
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study..
7.
2017
-
Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma..
4.
2014
-
Are thrombosis, progression, and survival in ET predictable?
2024
-
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
2022
-
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.
2020
-
Acute myeloid leukemia targets for bispecific antibodies.
2017
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)